key: cord-0952178-lv0cvpy7
authors: Thondapu, Vikas; Montes, Daniel; Rosovsky, Rachel; Dua, Anahita; McDermott, Shaunagh; Lu, Michael T.; Ghoshhajra, Brian; Hoffmann, Udo; Gerhard-Herman, Marie Denise; Hedgire, Sandeep
title: Venous thrombosis, thromboembolism and biomarkers of inflammation and coagulation in COVID-19
date: 2020-11-12
journal: J Vasc Surg Venous Lymphat Disord
DOI: 10.1016/j.jvsv.2020.11.006
sha: d9eb3cbe56629b5be9f1311d6eb78d2b66fa81a1
doc_id: 952178
cord_uid: lv0cvpy7

OBJECTIVE: Coronavirus disease 2019 (COVID-19) is associated with abnormal inflammatory and coagulation markers, potentially mediating thrombotic events. The objective was to investigate the incidence, time course, laboratory features, and in-hospital outcomes of COVID-19 patients with suspected venous thromboembolism (VTE). METHODS: A retrospective observational cohort study was conducted in patients hospitalized with COVID-19 undergoing ultrasound imaging for suspected VTE between March 13 to May 18, 2020. Medical records of included patients were reviewed for D-dimer, fibrinogen, prothrombin time, partial thromboplastin time, platelet count, C-reactive protein (CRP), and high-sensitivity troponin T at admission and up to 7 timepoints before and after ultrasound. Clinical outcomes included superficial venous thrombosis (SVT), deep venous thrombosis (DVT), pulmonary embolism (PE), intubation, and death. Mixed-effects logistic, linear, and Cox proportional hazards methods were used to evaluate the relation between laboratory markers with VTE and other in-hospital outcomes. RESULTS: Of 138 patients undergoing imaging, 44 (31.9%) had evidence of VTE. In univariable analysis, elevated admission CRP ([for every 10-unit increase in CRP] odds ratio [OR] 1.05, 95% confidence interval [CI] 1.01-1.09, p=0.02), platelets ([for every 1000-unit increase in platelets] OR 1.48, 95% CI 1.04-2.12, p=0.03), and male sex (OR 2.64, 95% CI 1.19-5.84, p=0.02), were associated with VTE. However only male sex remained significant in multivariable analysis (OR 2.37, 95% CI 1.01-5.56, p=0.048). Independent predictors of death included older age (HR 1.04, 95% CI 1.00-1.07, p=0.04), active malignancy (HR 4.39, 95% CI 1.39-13.91, p=0.01), elevated admission D-dimer (HR 1.016, 95% CI 1.003-1.029, p=0.02), and evidence of disseminated intravascular coagulation (DIC) (HR 4.81, 95% CI 1.76-13.10, p=0.002). CONCLUSIONS: Male sex, elevated CRP and platelet count at admission are associated with VTE in univariable analysis, but only male sex remained significant in multivariable analysis. Older age, active malignancy, DIC and elevated D-dimer at admission are independently associated with death in patients hospitalized with COVID-19.

and VTE in the progression of COVID-19 may refine treatment decisions, anticoagulation 1 strategies, resource management, and overall prognostication of these patients. 2

We therefore investigated the incidence, time course, and relationship of inflammatory 3 and coagulation markers with VTE and in-hospital outcomes in patients admitted with COVID-4 19 . 5 6 Methods 7

This retrospective two-center cohort study was approved by our institutional review 9 board (IRB) with a waiver for informed consent. We included consecutive patients >18 years old 10 admitted to two large academic hospitals between March 13, 2020 and May 18, 2020 with 11 polymerase chain reaction (PCR)-confirmed SARS-CoV2 infection who underwent 12 ultrasonographic evaluation for venous thrombosis in upper and lower extremities during the 13 same admission. Importantly, the decision to perform ultrasound or CT pulmonary angiography 14 were also recorded for up to 7 timepoints before and after ultrasound, with the date of ultrasound 5 taken as the reference timepoint. Patients were evaluated for disseminated intravascular 6 coagulation (DIC) using the International Society of Thrombosis and Haemostasis (ISTH) 7 criteria; DIC was defined as a score ≥5. 20 8

All venous ultrasound studies were performed with either Zonare ZS3 (Mindray, 9

Shenzhen, China), LOGIQ E9 or LOGIQ E10 (General Electric Medical Systems, Milwaukee, 10 USA) scanners. Deep venous thrombosis was diagnosed if there was inability to compress a 11 venous segment under gentle ultrasound probe pressure. 21, 22 CTPA was performed with 64-or 12 higher slice multidetector CT scanners. 13

14

The primary outcome of interest was incidence of VTE, defined as a composite of SVT, 16 DVT, and PE. Other outcomes included a composite of DVT and PE only, ICU admission, 17 length of hospitalization, invasive mechanical ventilation and death during the same 18 hospitalization. Patients were followed until death, discharge, or August 7, 2020, whichever 19 occurred first. 20 Categorical variables are presented as counts and percentages. Continuous variables were 1 analyzed using the Shapiro-Wilk test and presented as median and interquartile range (IQR). 2

Descriptive analyses of clinical variables and laboratory values were performed using Wilcoxon 3 rank-sum test or Fisher's Exact test as appropriate. Mixed-effects logistic regression was used to 4 assess the association of clinical and laboratory factors in relation to VTE, with a random 5 patient-level intercept to account for patients with multiple imaging scans. Linear regression was 6 used to analyze length of stay in relation to clinical and laboratory factors. Exploratory clinical 7 endpoints of intubation and death were assessed using Cox logistic regression. Patients 8 discharged, deceased, or still hospitalized as of August 7, 2020 were censored at the respective 9 date of occurrence. Factors associated with a p-value <0.05 in univariable analysis were included 10 in multivariable analysis. Trends in laboratory values were assessed using the generalized 11 estimating equations (GEE) to analyze repeated measures over time. Results are presented as 12 odds ratios (OR), hazard ratios (HR), or β-coefficients, as appropriate, with 95% confidence 13 intervals (CI). All tests were two-tailed with an α-level of 0.05 indicating statistical significance. 14 Statistical calculations were performed using R (2019, version 3.6.2) and MATLAB 2019b 15 (Mathworks, Natick, Massachusetts). The lme4 package was used for mixed-effects logistic 16 regression and GEE analysis was performed in using the GEEQBOX Statistical Toolbox. 23 suspected VTE and were assessed for study inclusion. Of these, 11 patients were excluded due 23 pregnancy (n = 10) and no laboratory data (n = 1), leaving 138 patients (165 ultrasound scans) in 1 the final analysis (Supplemental Figure 1 ). Of these, 117 (70.9%) were lower extremity and 48 2 (29.1%) were upper extremity scans. The most common indication for obtaining an ultrasound 3 was pain and/or swelling in the limb. Pharmacologic thrombosis prophylaxis was being 4 administered in 126 (91.3%) patients prior to imaging. Of these, 83 (60.1%) received a 5 subcutaneous low molecular weight heparin (LMWH), 28 (20.3%) received subcutaneous 6 heparin, and 10 (7.2%) received pharmacologic prophylaxis but the specific drug was not 7 mentioned in the medical chart. Additionally, 5 patients (3.6%) were on chronic anticoagulation 8 (3 [2.2%] were on direct oral anticoagulants and 2 [1.4%] were on coumadin) due to history of 9 prior venous thromboembolism, atrial fibrillation or other indication. Twelve patients (8.7%) had 10 contraindications to pharmacologic thrombosis prophylaxis including recent or acute 11 gastrointestinal bleeding and thrombocytopenia. Patient characteristics are shown in Table I Male sex, ICU admission, and intubation were significantly higher in patients with VTE 8 ( Table II) . Analysis of overall trends over time in laboratory tests showed that D-dimer 9 decreased in both groups (ß -107.9, 95% CI -211.6 to -4.17, p=0.04) while PTT increased (ß 10 2.02, 95% CI 0.002-4.05, p=0.05) (Supplemental Table I only male sex remained significant in multivariable analysis (Table III) . 21

Elevated admission D-dimer and aPTT were associated with increased hazard for 22 intubation by univariable analysis, but only D-dimer remained significant in multivariable 23 analysis (HR 1.01, 1.001-1.02, p=0.04) ( Table IV) . Male sex and intubation were independently 1 associated with increased length of stay (Supplemental Table IV) . By multivariable analysis, 2 independent predictors of death included increasing age (HR 1.04, 95% CI 1.00-1.07, p=0.04), 3 active malignancy (HR 4.39, 95% CI 1.39-13.91, p=0.01), DIC (HR 4.81, 95% CI 1.76-13.1, 4 p=0.002) and elevated admission D-dimer (HR 1.016, 95% CI 1.003-1.029, p=0.02). Elevated 5 admission CRP showed a trend towards increased risk of death, but this was not statistically 6 significant ( Table V) . Venous thromboembolism was not associated with increased length of 7 stay or death. 8 9

The primary findings of this study were: 1) incidence of VTE in COVID-19 patients 11 undergoing ultrasound or CTPA due to clinical suspicion was 32% despite thrombosis 12 prophylaxis; 2) the median time from COVID-19 symptom onset to diagnosis of VTE was 13.5 13 days; 3) male sex and elevated admission CRP and platelets were associated with VTE by 14 univariable analysis, but only male sex remained significantly associated in the multivariable 15 analysis; 4) older age, active malignancy, DIC, and elevated D-dimer at admission are 16 independently associated with death; 5) VTE was not associated with increased length of stay or 17 death. 18

Studies of VTE rates in critically-ill patients prior to the COVID-19 pandemic report an 19 incidence of 16% upon clinically-indicated imaging 26 and from 8 to 37% in prospectively 20 screened patients regardless of symptoms. 27-29 Recent studies suggest hospitalized COVID- 19 21 patients have an increased predisposition for thrombotic events, with an incidence ranging from 22 20-36% in the subset receiving clinically-indicated imaging. 13-18 However, in a more general 23 cohort of COVID-19 patients, the VTE incidence is 4.8%, 9 but is as high as 85% in those 1 receiving ultrasound screening exams regardless of clinical suspicion. 30 In an Italian cohort of 2 ICU and general ward patients, 16 of 44 patients (36%) who underwent clinically-indicated 3 imaging were diagnosed with VTE. 13 Another study of 198 patients demonstrated an 20% 4 incidence of VTE in ICU and general ward patients 15 while a third study of 184 patients admitted 5

to the ICU reported a 27% incidence of VTE. 14 The number of patients imaged was not explicitly 6 reported in either of these latter studies. Finally, an 85% incidence of lower extremity DVT was 7 reported in a study of 48 patients with severe COVID-19 admitted to the ICU who were screened 8 at least twice with lower extremity ultrasound regardless of symptoms. 30 9

We specifically investigated patients who underwent imaging due to clinical suspicion 10 and found the overall incidence of any VTE was 32%. We note that the overall incidence is 11 similar to prior studies despite longer median follow-up (40 days versus 7, 14 7, 15 and 10 13 , 12 17 12 days). The added context of our observation that the median time from COVID-19 symptom 13 onset to positive diagnosis of VTE was 13.5 days, raises the possibility that the risk peaks at 14 approximately 2-weeks after symptom onset. The caveat in comparing these studies, however, is 15 that the proportion of patients still hospitalized and remaining at risk for VTE varied 16 considerably: 1.4% in the current study versus 6.7%, 13 8%, 15 10%, 17 and 76%. 14 Nevertheless, 17 the current and previous studies together suggest a lower threshold of clinical suspicion for VTE 18 in these patients may be indicated, particularly in the second and third weeks after symptom 19 onset. 20

The propensity for thromboembolic events in COVID-19 patients is mirrored by 21 abnormal hematologic and coagulation markers indicating an induced hypercoagulable state. At 22 least one previous study has shown an independent association of elevated white blood cell 23 J o u r n a l P r e -p r o o f count, neutrophil-to-lymphocyte ratio, and D-dimer with VTE. 15 In another study, coagulopathy, 1 defined by the authors as prolongation of PT > 3 seconds or activated PTT >5 seconds, was 2 associated with an adjusted HR of 4.1 (95% CI 1.9-9.1) for thrombotic events. 14 In our study, 3 higher maximum and day of ultrasound PTT were attributed to initiation of therapeutic 4 anticoagulation after VTE was diagnosed. Instead, in the univariable analysis, we observed an 5 association of elevated admission CRP and platelet count with subsequent VTE, while D-dimer 6 was not associated. While admission CRP and platelet count did not remain associated in the 7 multivariable analysis, suggesting that male sex (which remained significant) affects these 8 laboratory variables, we note that there was a trend towards significance for admission CRP in 9 the multivariable analysis (p=0.06). Larger studies may be better poised to investigate this signal. 10

Noting that only 8 patients in our study met ISTH criteria for consumptive coagulopathy, Interestingly, elevated admission D-dimer was not associated with venous thrombosis in our 18 study, but instead was independently associated with need for mechanical ventilation and death. 19

These results suggest that D-dimer may be more reflective of overall disease severity than 20 elevations in severe COVID-19. 2, 5, 19 CRP is also one among several laboratory abnormalities 1 associated with severity of lung injury 32 and lung lesions 33 in COVID-19 patients. 2

There are several limitations of this study. First is the retrospective design, which 3 contributed to variable laboratory data as dictated by standard of care assessment during 4 hospitalization. In the context of attempting to mitigate exposure of healthcare workers, we also 5 acknowledge that shifting clinical thresholds for ordering ultrasound might have affected the 6 number and characteristics of patients receiving imaging. 34 A prospective study design 7 mandating standardized collection intervals would alleviate these limitations. Second, because 8 our primary hypotheses were specifically focused on the features of suspected VTE in the setting 9 of SARS-CoV2 infection, we did not include COVID-positive patients who did not undergo 10 imaging. Therefore, we do not know the true incidence of VTE in all COVID-19 patients, and 11

whether the findings of this study are applicable to a more generalized population of COVID-19 12 patients remains unaddressed. However, to our knowledge, this is one of the largest cohorts to 13 date of COVID-19 patients with imaging for VTE. Third, the follow-up period was limited to 14 hospitalization only, therefore we do not know whether COVID-19 patients remain at elevated 15 risk for VTE after discharge. However, in a recent retrospective study evaluating the post-16 discharge rate of thrombosis in patients with COVID-19, the cumulative incidence of venous 17 thromboembolism alone at day 30 post-discharge was 0.6% (95% CI 0.1-4.6). 35 The incidence of venous thromboembolism in hospitalized COVID-19 patients 5 undergoing imaging was 32%, and the median time from symptom onset to diagnosis of VTE 6 was 13.5 days. Male sex, elevated CRP and platelet count at admission were associated with 7 venous thromboembolism in the univariable analysis, but only male sex remained significantly 8 associated in the multivariable analysis. Elevated D-dimer at admission was independently 9 associated with intubation and death in these patients, while older age, active malignancy, and 10 disseminated intravascular coagulation were also independently associated with death. These Tables   Table I: 

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Laboratory Markers -Day of Ultrasound D-dimer (ng/mL) 4000 (2605

Laboratory Markers -Maximum Value D-dimer

Laboratory Markers -Minimum Value Fibrinogen (mg/dL) 549 (468, 672) 551.5 (429.8, 718)